Inaqovi

Decitabine, the active ingredient in Inaqovi, is a DNA methyltransferase inhibitor (hypomethylating agent) presented as a fixed‑dose oral tablet containing 35 mg decitabine and 100 mg cedazuridine for oral administration. It is indicated for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in adult patients.

GNH USA supplies Inaqovi as a licensed, GMP‑qualified, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units and retail pharmacies worldwide, with support for regulatory documentation and timely delivery.

Inaqovi is used in hematologic malignancies that involve abnormal DNA methylation.

Myelodysplastic syndromes: improves blood counts and may reduce transfusion dependence. Chronic myelomonocytic leukemia: reduces disease burden and prolongs survival. Adult patients with intermediate‑ or high‑risk disease: provides disease‑modifying therapy that can delay progression to acute leukemia.

Adverse reactions may occur with Inaqovi treatment.

Common Side Effects: - Nausea - Fatigue - Diarrhea - Neutropenia (low white‑blood‑cell count)

Serious or Rare Side Effects: - Severe infections due to profound myelosuppression - Elevated liver enzymes indicating hepatic injury - Pulmonary toxicity such as interstitial pneumonitis

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood counts: perform regular complete blood count assessments. Assess liver function: check hepatic enzymes prior to and during treatment. Evaluate renal function: adjust use if severe impairment is present. Avoid in patients with active uncontrolled infection: risk of worsening infection. Use effective contraception: potential teratogenicity is unknown. Store at below 25°C: keep in the original pack, protect from moisture.

Inaqovi may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Co‑administration with other hypomethylating agents: additive myelosuppression. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antacids: may affect oral absorption of cedazuridine. - NSAIDs or anticoagulants: heightened bleeding tendency. - Strong CYP3A4 inhibitors: potential increase in cedazuridine levels.